M. Lopez

2.4k total citations · 1 hit paper
42 papers, 1.6k citations indexed

About

M. Lopez is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Immunology. According to data from OpenAlex, M. Lopez has authored 42 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Cardiology and Cardiovascular Medicine, 11 papers in Molecular Biology and 10 papers in Immunology. Recurrent topics in M. Lopez's work include Cardiac Fibrosis and Remodeling (8 papers), IL-33, ST2, and ILC Pathways (6 papers) and Chemotherapy-induced cardiotoxicity and mitigation (6 papers). M. Lopez is often cited by papers focused on Cardiac Fibrosis and Remodeling (8 papers), IL-33, ST2, and ILC Pathways (6 papers) and Chemotherapy-induced cardiotoxicity and mitigation (6 papers). M. Lopez collaborates with scholars based in Spain, United States and France. M. Lopez's co-authors include Domingo A. Pascual‐Figal, Antonio Lax, Juan G. Álvarez, Mario Ollero, Ashok Agarwal, Rakesh Sharma, Jesús Sánchez‐Más, Anthony J. Thomas, A.J. Thomas and Fernando Soler and has published in prestigious journals such as Journal of the American College of Cardiology, PLoS ONE and Scientific Reports.

In The Last Decade

M. Lopez

40 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Colchicine prevents accelerated atherosclerosis in TET2-mutant clonal haematopoiesis

2024 36 citations María A. Zuriaga, Zhi Yu et al. European Heart Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Lopez Spain	19	600	472	421	310	242	42	1.6k
Hakan Kültürsay Türkiye	22	62 0.1×	206 0.4×	329 0.8×	332 1.1×	303 1.3×	86	1.6k
MA Siimes Finland	25	58 0.1×	279 0.6×	155 0.4×	584 1.9×	71 0.3×	46	1.8k
Kam Tong Leung Hong Kong	26	54 0.1×	86 0.2×	118 0.3×	674 2.2×	474 2.0×	63	1.9k
A Struyvenberg Netherlands	24	85 0.1×	47 0.1×	82 0.2×	294 0.9×	182 0.8×	60	1.6k
Mohamed Ali Egypt	24	667 1.1×	108 0.2×	14 0.0×	361 1.2×	105 0.4×	113	1.6k
Yi‐Cheng Wang China	20	39 0.1×	141 0.3×	54 0.1×	433 1.4×	108 0.4×	95	1.3k
Ioannis Tentes Greece	23	41 0.1×	47 0.1×	255 0.6×	482 1.6×	270 1.1×	71	1.5k
Anna Stelmaszczyk‐Emmel Poland	16	28 0.0×	62 0.1×	128 0.3×	239 0.8×	283 1.2×	84	1.2k
Lijuan Hu China	23	48 0.1×	48 0.1×	71 0.2×	793 2.6×	188 0.8×	112	1.5k
Alicia Hernández Spain	19	400 0.7×	42 0.1×	36 0.1×	157 0.5×	97 0.4×	113	1.2k

Countries citing papers authored by M. Lopez

Since Specialization

Citations

This map shows the geographic impact of M. Lopez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Lopez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Lopez more than expected).

Fields of papers citing papers by M. Lopez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Lopez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Lopez. The network helps show where M. Lopez may publish in the future.

Co-authorship network of co-authors of M. Lopez

This figure shows the co-authorship network connecting the top 25 collaborators of M. Lopez. A scholar is included among the top collaborators of M. Lopez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Lopez. M. Lopez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lopez, M., Yassine Sassi, José J. Fuster, et al.. (2025). AEOL-induced NRF2 activation and DWORF overexpression mitigate myocardial I/R injury. Molecular Medicine. 31(1). 189–189. 1 indexed citations

Zuriaga, María A., Zhi Yu, Nuria Matesanz, et al.. (2024). Colchicine prevents accelerated atherosclerosis in TET2-mutant clonal haematopoiesis. European Heart Journal. 45(43). 4601–4615. 36 indexed citations breakdown →

Lax, Antonio, Fernando Soler, María Josefa Fernández del Palacio, et al.. (2023). Silencing of microRNA-106b-5p prevents doxorubicin-mediated cardiotoxicity through modulation of the PR55α/YY1/sST2 signaling axis. Molecular Therapy — Nucleic Acids. 32. 704–720. 4 indexed citations

Lopez, M., Mario Royo-Villanova, Fernando Soler, et al.. (2022). Critical warm ischemia time point for cardiac donation after circulatory death. American Journal of Transplantation. 22(5). 1321–1328. 29 indexed citations

Pascual‐Figal, Domingo A., Antoni Bayés‐Genís, Álvaro Hernández Vicente, et al.. (2021). Clonal Hematopoiesis and Risk of Progression of Heart Failure With Reduced Left Ventricular Ejection Fraction. Journal of the American College of Cardiology. 77(14). 1747–1759. 132 indexed citations

Lopez, M., Antonio Lax, Álvaro Hernández Vicente, et al.. (2020). Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status. Scientific Reports. 10(1). 13553–13553. 28 indexed citations

Lopez, M., Antonio Lax, Álvaro Hernández Vicente, et al.. (2020). Author Correction: Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status. Scientific Reports. 10(1). 17266–17266. 3 indexed citations

Pascual‐Figal, Domingo A., Antoni Bayés‐Genís, M. Lopez, et al.. (2019). The Interleukin-1 Axis and Risk of Death in Patients With Acutely Decompensated Heart Failure. Journal of the American College of Cardiology. 73(9). 1016–1025. 56 indexed citations

Lopez, M., Antonio Lax, María Josefa Fernández del Palacio, et al.. (2019). Yin-Yang 1 transcription factor modulates ST2 expression during adverse cardiac remodeling post-myocardial infarction. Journal of Molecular and Cellular Cardiology. 130. 216–233. 17 indexed citations

10.

Pascual‐Figal, Domingo A., M. Lopez, Jesús Sánchez‐Más, et al.. (2018). Pulmonary Production of Soluble ST2 in Heart Failure. Circulation Heart Failure. 11(12). e005488–e005488. 59 indexed citations

11.

Lopez, M., Antonio Lax, María Josefa Fernández del Palacio, et al.. (2018). Pharmacological inhibition of the mitochondrial NADPH oxidase 4/PKCα/Gal-3 pathway reduces left ventricular fibrosis following myocardial infarction. Translational research. 199. 4–23. 22 indexed citations

12.

Sánchez‐Más, Jesús, Antonio Lax, M. Lopez, et al.. (2017). Early Anti-inflammatory and Pro-angiogenic Myocardial Effects of Intravenous Serelaxin Infusion for 72 H in an Experimental Rat Model of Acute Myocardial Infarction. Journal of Cardiovascular Translational Research. 10(5-6). 460–469. 7 indexed citations

13.

Lopez, M., Fernando Soler, Domingo A. Pascual‐Figal, Francisco Fernández-Belda, & Antonio Lax. (2017). Doxorubicin-induced oxidative stress: The protective effect of nicorandil on HL-1 cardiomyocytes. PLoS ONE. 12(2). e0172803–e0172803. 117 indexed citations

14.

Pérez‐Calvo, Juan Ignacio, et al.. (2015). Ausencia de implicación de la cistatina C en el remodelado ventricular y la insuficiencia cardiaca. Revista Clínica Española. 216(2). 55–61.

15.

Lax, Antonio, Jesús Sánchez‐Más, M. Lopez, et al.. (2014). Mineralocorticoid Receptor Antagonists Modulate Galectin-3 and Interleukin-33/ST2 Signaling in Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction. JACC Heart Failure. 3(1). 50–58. 87 indexed citations

16.

Lopez, M., et al.. (2012). Involvement of ferritin heavy chain in the preventive effect of metformin against doxorubicin-induced cardiotoxicity. Free Radical Biology and Medicine. 57. 188–200. 41 indexed citations

17.

Lopez, M., Antonio Lax, Domingo A. Pascual‐Figal, Mariano Valdés, & Jesús Sánchez‐Más. (2011). Metformin protects against doxorubicin-induced cardiotoxicity: Involvement of the adiponectin cardiac system. Free Radical Biology and Medicine. 51(10). 1861–1871. 85 indexed citations

18.

Álvarez, Juan G., Rakesh Sharma, Mario Ollero, et al.. (2002). Increased DNA damage in sperm from leukocytospermic semen samples as determined by the sperm chromatin structure assay. Fertility and Sterility. 78(2). 319–329. 117 indexed citations

19.

Touboul, P, Xavier André-Fouët, Alain Leizorovicz, et al.. (1997). Risk stratification after myocardial infarction: A reappraisal in the era of thrombolysis. European Heart Journal. 18(1). 99–107. 43 indexed citations

20.

Ferber, Christian von, et al.. (1988). Intérêt de la mesure transcutanée des gaz du sang au cours des fibroscopies bronchiques en réanimation. Annales Françaises d Anesthésie et de Réanimation. 7(1). 42–45. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact